SV de­buts a new, $400M fund with a big fo­cus on biotech star­tups

Af­ter tweak­ing its name, SV Health In­vestors un­veiled its sixth main fund with $400 mil­lion, a step down from its last big raise way back in 2010.

SV is best known for its biotech plays as an ac­tive in­vestor in the start­up com­mu­ni­ty. But the ven­ture firm al­so tar­gets med­ical de­vices, dig­i­tal health and health­care ser­vices, which is one rea­son it dropped Life Sci­ences from the name.

SV has of­fices root­ed in the three big glob­al hubs: Lon­don, Cam­bridge, MA and San Fran­cis­co. It has backed com­pa­nies like Mi­cromet — bought out by Am­gen for $1.16 bil­lion — along with In­cyte, Achillion and Shire in the ear­ly days. Its cur­rent in­vest­ments in­clude Sutro, Kalvista and Cataba­sis, which has had to grap­ple with some re­cent set­backs in the clin­ic, in­clud­ing a flop for Duchenne mus­cu­lar dy­s­tro­phy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.